Search

Now showing items 1-4 of 4

Marked neutropenia: Significant but rare in people with multiple sclerosis after alemtuzumab treatment.

Baker, D; Giovannoni, G; Schmierer, K (2017-11)

BACKGROUND: Alemtuzumab is a CD52-specific monoclonal antibody that markedly depletes T and B lymphocytes and inhibits relapsing multiple sclerosis (MS). However, polymorphonuclear neutrophils also express CD52 and can be ...

Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.

Coles, AJ; Cohen, JA; Fox, EJ; Giovannoni, G; Hartung, H-P; Havrdova, E; Schippling, S; Selmaj, KW; Traboulsee, A; Compston, DAS;... (2017-09-12)

OBJECTIVE: To evaluate 5-year efficacy and safety of alemtuzumab in patients with active relapsing-remitting multiple sclerosis and inadequate response to prior therapy. METHODS: In the 2-year Comparison of Alemtuzumab and ...

Validation of an environmentally-friendly and affordable cardboard 9-hole peg test.

Dubuisson, N; Bauer, A; Buckley, M; Gilbert, R; Paterson, A; Marta, M; Gnanapavan, S; Turner, B; Baker, D; Giovannoni, G;... (2017-10)

BACKGROUND: In multiple sclerosis (MS) upper limb neurological impairments, are an important driver of disability and handicap. The gold standard for assessing upper limb function is the 9-hole peg test (9HPT). One ...

How to start a blog.

Thomson, A; Raciborska, D; Baker, D; Giovannoni, G (2017-06)

Blogs that address issues of health and medical education run by clinical and research teams can have a profound impact on how patients access and navigate health information. Regularly updated websites are useful tools ...